Shida Shangguan

Shida Shangguan

Auto-generated profile, based on publicly available information

Shida Shangguan

U.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Research Silver Spring Maryland USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
PEPhilip K. Ehrenberg
Philip K. Ehrenberg
SSShida Shangguan
Shida Shangguan
BIBiju Issac
Biju Issac
GAGalit Alter
Galit Alter
AGAviva Geretz
Aviva Geretz
RTRasmi Thomas
Rasmi Thomas
A gene signature in B cells associates with protective efficacy of different vaccine regimens against SIV and HIV infection.

2 August 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
AGAviva Geretz
Aviva Geretz
PEPhilip K. Ehrenberg
Philip K. Ehrenberg
RCRobert J. Clifford
Robert J. Clifford
ALAlexandre Laliberté
Alexandre Laliberté
CBCaterina Prelli Bozzo
Caterina Prelli Bozzo
RTRasmi Thomas
Rasmi Thomas
Host restriction factors play key roles in innate antiviral defense, but it remains poorly understood which of them restricts HIV-1 in vivo. Here, we used single-cell transcriptomic analysis to identify host factors associated with HIV-1 control during acute infection by correlating host gene expression with viral RNA abundance within individual cells. Wide sequencing of cells from one participant with the highest plasma viral load revealed that intracellular viral RNA transcription correlates inversely with expression of the gene PTMA , which encodes prothymosin α. This association was genome-wide significant ( P adjusted < 0.05) and was validated in 28 additional participants from Thailand and the Americas with HIV-1 CRF01_AE and subtype B infections, respectively. Overexpression of prothymosin α in vitro confirmed that this cellular factor inhibits HIV-1 transcription and infectious virus production. Our results identify prothymosin α as a host factor that restricts HIV-1 infection in vivo, which has implications for viral transmission and cure strategies.

10 August 2025 in Journal of the International AIDS Society
Verified
Journal Article
Open access
YLYifan Li
Yifan Li
BDBethany L. Dearlove
Bethany L. Dearlove
ELEric Lewitus
Eric Lewitus
HBHongjun Bai
Hongjun Bai
SSShida Shangguan
Shida Shangguan
MRMorgane Rolland
Morgane Rolland
Introduction: Cases of spontaneous control of HIV‐1 can help define strategies to induce remission. Since the identification of viral control in the absence of treatment typically occurs after a prolonged period post‐HIV‐1 diagnosis, our knowledge of the early events after HIV‐1 acquisition that led to viral control is limited. Methods: The RV217 prospective cohort enrolled 2276 participants in East Africa (Kenya, Uganda, Tanzania) and Thailand between 2009 and 2015. We analysed HIV‐1 sequences and clinical data from 102 individuals who were diagnosed with acute HIV‐1 infection and had a negative HIV‐1 RNA test in the week before. We focused on 69 participants with longitudinal follow‐up and identified viraemic controllers who maintained viral loads <2000 copies/ml for over a year without treatment. We evaluated viral genetic and clinical features that are associated with viral control. Results: Eleven women from East Africa showed control of viral replication for an average duration of 891 (range: 405–1425) days within an average of 130 days from diagnosis. The majority were living with subtype A1 ( n = 6), or A1 recombinant strains ( n = 4), with one living with subtype D; 10 were from Kenya, one from Uganda. Controllers had significantly slower CD4+ T cell decline ( p = 0.028) and higher Natural Killer (NK) cell counts ( p = 0.047) than non‐controllers, but none carried human leukocyte antigen (HLA) alleles previously reported to be associated with viral control. Peak viraemia was recorded at an average of 541 million copies/ml with no difference between controllers and non‐controllers ( p = 0.97). Viral loads became lower in controllers (3459 copies/ml) than in non‐controllers (23,157 copies/ml) as early as nadir viraemia ( p = 0.009), with a more significant difference observed at set point (1069 vs. 24,084 copies/ml, respectively; p <0.0001). Conclusions: Our findings confirm the role of HIV‐1 subtype A1 in mediating viral control. The fact that controllers showed high viral loads in acute infection indicates that these viruses were not intrinsically impaired for replication, underlining the intersection between host immunity and favourable genotypes in the subsequent control of HIV‐1. These data suggest that conducting HIV‐1 remission studies in East Africa could provide favourable conditions to achieve durable post‐treatment control of viraemia.